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•  Skin involvement is of major clinical and prognostic relevance in systemic 
sclerosis (SSc) 
•  Often the primary outcome in clinical trials in SSc 
•  Modified Rodnan Skin Score (mRSS) 
§  Semi-quantitative measure of cutaneous involvement assessed by palpation 
 
•  However, the mRSS has been criticized for: 
§  High intra- inter-observer variability (12% and 25%, respectively) 
§  Dependent on training and experience 
§  Cannot differentiate between three phases of the disease 
 
Introduction
A fully validated, objective and sensitive measure of skin involvement is lacking.  
•  Elastography is a new ultrasound-based imaging modality that has aroused the interest 
of researchers in ultrasound imaging technology during the last two decades: 
§  Compression elastography 
§  Shear-wave elastography 
 
•  Shear-wave elastography provides quantitative measurements of tissue stiffness by 
measuring the velocity of propagation of a shear-wave in tissues 
§  Virtual Touch Imaging and Quantification (VTIQ) 
ü  (More) operator independent  
ü  Absolute values 
ü  Allows the use of small adjustable sampling gates in order to assess discrete anatomical 
structures  
 
Shear-wave elastography 
We hypothesize that VTIQ may provide a non-invasive sensitive means for absolute 
quantification of skin stiffness, which may have considerable impact upon clinical 
practice and research in SSc.  
•  To compare absolute skin stiffness values of clinically 
unaffected scleroderma skin and the skin of healthy 
controls, using shear-wave elastography. 
Objective
•  Participants 
§  26 SSc patients  
§  17 HC (age- and gender-matched) 
•  Rodnan skin score 
§  Skin thickness measured over 17 anatomical anatomical sites 
•  Ultrasound evaluation  
§  Absolute skin stiffness (shear-wave velocity, (in m/s) was measured at all mRSS anatomical sites  
§  Siemens ACUSON S3000TM ultrasound system with a linear 4-9MHz transducer. Sampling gates sized 
2x2mm.  
•  Reliability  
§  Intra-observer reliability was assessed by intraclass correlation coefficients (ICC) in 4 SSc patients at all 
17 sites and 2 healthy controls, in 2 sequential scanning sessions, one week apart. 
 
•  Statistical analysis  
§  SPSS version 20.0. Mann-Whitney test was used to evaluate differences between groups. P value <0.05 
were considered significant. 
Methods
Results (I)
SSc patients  Controls  
Gender (F/M)  23/3  14/3  
Age, mean (SD) (years)  55.3 (12.1)  54.3 (14.8)  
Disease duration from RP, mean (SD) (years)  14.9 (9.4)  
Disease duration from diagnosis, mean (SD) 
(years)  
12.5 (8.7)  
Disease subset (D/L)  13/13  
ANA, n (%)  26 (100.0)  
ACA, n (%)  10 (38.5)  
Anti-topoisomerase I, n (%)  9 (34.6)  
Anti-PMScl, n (%)  2 (7.7)  
mRSS, mean (SD)/range  11.8 (9.2)/0–33  
ACA, Anticentromere antibodies; ANA, Antinuclear antibodies; D, Diffuse cutaneous SSc; L, Limited 
cutaneous SSc; RP, Raynaud's Phenomenon. 
Results (II) 
Shear-wave elastography of the dorsal aspect of the hand.
(A)  Healthy Control                                         (B) Patient 
 
Results (III) - Shear wave velocities values (m/s) in unaffected skin 
from SSc patients vs. Controls
P values were obtained by t-test. NS – non significant. 
SSc patients 
n= 26 (*) 
Controls 
n= 17 
P 
Anterior 
chest 
2.8±0.7 (17) 2.3±0.7  NS 
Abdómen 2.5±0.4 (21)  2.1±0.4  0.024 
Upperarm 2.4±0.4  (19) 2.2±0.3  NS 
Forearm 2.6±0.3 (14)  2.1±0.3  0.053 
Hand 2.6±0.6 (7)  2.2±0.3 NS 
Phalanx 2.9±0.3 (3)  2.1±0.2  0.006 
Thigh 2.4±0.4 (18)  2.1±0.2 0.002 
Leg 2.4±0.6 (18)  2.3±0.3  NS 
Foot 2.8±0.6 (14)  2.3±0.3  0.004 
*Number of patients with mRSS = 0 at each site. 
Results (IV) – Shear-wave velocity values according to 
clinical skin score.
N1=        257            221           101             60             19 
1Total number of skin sites with this clinical classification.* = P < 0.05, ** = P < 0.01 
* 
•  Our results indicate that shear-wave elastography is capable of identifying 
significantly increased stiffness in skin from SSc patients as measured 
in sites considered clinically 'unaffected'.  
•  This study provides the first quantitative and objective measurement of 
absolute skin stiffness in SSc.  
•  This is in agreement with recent microarray gene expression studies 
suggesting that clinically unaffected skin shares the peculiar gene signatures 
and the pathology of clinically affected skin in SSc [Frost J, et al 2012; Pendergrass SA 2012, 
Milano, 2008]  
•  This increased sensitivity of shear-wave elastography in the early stages of 
skin involvement may represent a valuable contribution to clinical 
assessment and especially, to research in the pathogenesis and treatment of 
this disease.  
Discussion
•  These findings strongly supports that shear-wave elastography represents 
valuable progress in the quantitative assessment of skin stiffness.  
•  It adds sensitivity and precision to the non-invasive assessment of skin 
involvement in SSc, which may be decisive in the evaluation of new 
interventions. 
•  Longitudinal studies in a large number of patients, with multiple 
independent observers, are needed to assess inter-observer reliability and 
sensitivity to change over time.  
•  Such studies, together with technical improvements in the methodology, may 
well establish VTIQ as a valuable quantitative outcome measure for 
clinical and research work in SSc.  
Conclusion
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